We are investigating the fairness of the proposed sale of Cross Country Healthcare (Nasdaq: CCRN) (“CCRN”) for $13.25 per share in cash to Knox Lane, a private equity firm.
The sale price is below CCRN’s 52-week high of $14.99 per share, which indicates an opportunistic purchase.
Additionally, CCRN had previously reached an agreement in December 2024 to be acquired by Aya Healthcare for $18.61 per share in cash. That agreement was terminated in December 2025
If you remain a CCRN shareholder and have concerns about the fairness of the sale price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
“We are investigating whether the CCRN board of directors acted in the best interests of CCRN shareholders in recommending the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the sale price is fair to CCRN shareholders, and whether all material information regarding the transaction has been fully disclosed. We encourage CCRN shareholders to contact the firm if they have any concerns.”